ArticleScientific reports2026
Combining glycine with thymoquinone offers a promising strategy for diabetes treatment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is increasing globally, and current treatments are frequently associated with high costs and harmful side effects. Researchers are exploring safer, natural alternatives as thymoquinone and glycine. Glycine, the simplest proteinogenic amino acid, and thymoquinone, the active compound in Nigella sativa, have shown promising hypoglycemic, antioxidant, and anti-inflammatory properties. A combination of glycine and thymoquinone for treating diabetes was not investigated before. This work studies the biochemical and histopathological effects of thymoquinone and glycine administered in combination in a diabetic rat model. Diabetes mellitus was induced by streptozotocin (STZ). Five rat groups were used: control healthy, diabetes, diabetic rats treated with glycine (G) or thymoquinone (Q), or the combination (Q + G) groups. Rat body weight changes, water and food intake, fasting blood glucose (FBG), hemoglobin (Hb), glycated Hb (HbA1C), insulin, HOMA-IR, HOMA %B and HOMA %S, QUICKI, albumin, amylase, creatine kinase, TNF-α, IL-10, glucose-6-phosphatase, fructose 1,6-bisphosphatase, glucose-6-phosphat dehydrogenase, oxidative stress portrait, and pancreas histopathology were investigated. Treatment with glycine or thymoquinone or both significantly decreased FBG, oxidative stress, and inflammation and improved metabolic dysfunction compared to untreated diabetic group. It also, revealed cytoprotection to pancreas tissue and reduced inflammatory infiltration. Effects of thymoquinone and glycine treatments were appreciated, however effects of thymoquinone combined with glycine were much better. In conclusion, thymoquinone and glycine combination, can effectively reduce both blood sugar and diabetic-associated complications through their synergistic, strong antioxidant and anti-inflammatory properties, which support the body's natural cytoprotective ability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.